Celularity Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 27.3% | 95.1% | 95.1% | 11.2% | 79.3% | 41.8% | 40.5% | 40.5% | 91.4% | 38.2% | 179.7% | -108.5% | 53.0% | |
| 72.7% | 4.9% | 4.9% | 88.8% | 20.7% | 58.2% | 59.5% | 59.5% | 8.6% | 61.8% | -79.7% | 208.5% | 47.0% | |
| 292.9% | 136.9% | 136.9% | 39.8% | 892.3% | 42.1% | 21.1% | 21.1% | 58.4% | 87.0% | 81.6% | 81.6% | 76.2% | |
| 436.6% | 283.9% | 345.2% | 95.6% | 107.5% | 136.1% | 88.6% | 88.4% | 220.3% | 176.1% | 367.1% | – | – | |
| 1,518.4% | 530.5% | 2,626.5% | 150.2% | -89.3% | 182.2% | 152.2% | 110.7% | 285.2% | 305.9% | 637.5% | 746.0% | 464.4% | |
| -1,445.7% | -430.5% | -2,621.7% | -50.2% | 109.9% | -124.0% | -52.2% | -51.2% | -276.6% | -244.1% | -537.5% | -537.5% | -379.0% | |
| 37.6% | 25.6% | 25.6% | 7.8% | 5.5% | 18.8% | 10.0% | 10.0% | 33.9% | 28.0% | 21.9% | 21.9% | 27.1% | |
| -1,632.0% | -2,479.6% | -2,479.6% | -149.9% | 78.9% | -173.2% | -73.3% | -73.3% | -427.5% | -436.7% | -593.5% | -593.5% | -500.9% | |
| -108.8% | – | 55.8% | – | 0.1% | -145.1% | – | 74.4% | – | -0.1% | – | 0.1% | – | |
| -1,632.0% | -2,479.6% | -2,479.6% | -149.9% | 78.8% | -173.2% | -73.3% | -73.3% | -427.5% | -436.7% | -593.6% | -593.6% | -500.9% | |
| -1,515.4% | – | -2,392.0% | – | -70.6% | -134.0% | – | -41.9% | -361.7% | -373.4% | – | -527.8% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.